INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $382,554 | +43.3% | 28,485 | +47.2% | 0.00% | 0.0% |
| Q2 2022 | $267,000 | -31.2% | 19,355 | -18.9% | 0.00% | 0.0% |
| Q1 2022 | $388,000 | -74.5% | 23,855 | -61.3% | 0.00% | -85.7% |
| Q4 2020 | $1,524,000 | -69.3% | 61,718 | -48.4% | 0.01% | -65.0% |
| Q3 2020 | $4,963,000 | -20.4% | 119,697 | -8.0% | 0.02% | -35.5% |
| Q2 2020 | $6,235,000 | +293.9% | 130,138 | +918.8% | 0.03% | +520.0% |
| Q4 2019 | $1,583,000 | -33.2% | 12,774 | -64.2% | 0.01% | -44.4% |
| Q3 2019 | $2,368,000 | +314.0% | 35,688 | +396.2% | 0.01% | +350.0% |
| Q2 2019 | $572,000 | -67.9% | 7,192 | -54.8% | 0.00% | -71.4% |
| Q1 2019 | $1,781,000 | +271.0% | 15,927 | +234.5% | 0.01% | +250.0% |
| Q4 2018 | $480,000 | -12.4% | 4,762 | +9.8% | 0.00% | 0.0% |
| Q3 2018 | $548,000 | +29.9% | 4,338 | -13.7% | 0.00% | 0.0% |
| Q2 2018 | $422,000 | +29.4% | 5,024 | -5.2% | 0.00% | +100.0% |
| Q1 2018 | $326,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |